TriangleNCT03596645 · CITED IN SOURCE DOCUMENTS
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- ACTIVE NOT RECRUITING
- Registry last update
- 2026-08-31
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC). In addition, the safety profile of golimumab, in pediatric participants with moderately to severely active UC will be assessed.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Mayo Score
Percentage of Participants With Symptomatic Remission at Week 54
Percentage of Participants With Clinical Remission at Week 54 as Assessed by the Mayo Score
Percentage of Participants With Clinical Remission at Week 54 as Assessed by the Pediatric Ulcerative Colitis Activity Index Score (PUCAI) Score
Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Pediatric Ulcerative Colitis Activity Index Score (PUCAI) Score
Percentage of Participants With Clinical Response at Week 6 as Assessed by the Mayo Score
Percentage of Participants With Endoscopic Healing at Week 6 as Assessed by the Mayo Score
Percentage of Participants With Endoscopic Healing at Week 54 as Assessed by the Mayo Score
Percentage of Participants With Clinical Remission at Week 54 as Assessed by the Mayo Score for Participants Who Were in Clinical Remission at Week 6
Percentage of Participants Who Were Not Receiving Corticosteroids for at Least 12 Weeks Prior to Week 54 and in Clinical Remission at Week 54
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Must either be currently receiving treatment with, or have a history of having failed to respond to, or have a medical contraindication to at least 1 of the following therapies: oral or intravenous corticosteroids, 6-mercaptopurine, methotrexate or azathioprine OR must either have or have had a history of corticosteroid dependency (that is an inability to successfully taper corticosteroids without a return of the symptoms of ulcerative colitis \[UC\]) OR required more than 3 courses of corticosteroids in the past year * Moderately to severely active UC (as defined by baseline Mayo score of 6 through 12 \[endoscopy {sigmoidoscopy or colonoscopy} sub score assigned by local endoscopist\], inclusive), including a (sigmoidoscopy or colonoscopy) sub score greater than or equal to (\>=2) * If receiving enteral nutrition, must have been on a stable regimen for at least 2 weeks prior to the first administration of study intervention at Week 0. Participants who receive parenteral nutrition are not permitted to enroll in the trial * No history of latent or active tuberculosis prior to screening * Must be up to date with all immunizations (that is, measles, mumps, rubella, and varicella) in agreement with current local immunization guidelines for immunosuppressed participants before Week 0 Exclusion Criteria: * History of liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric (including suicidality), or metabolic disturbances * History of malignancy or macrophage activation syndrome or hemophagocytic lymphohistiocytosis * Have UC limited to the rectum only or to \<20 percent (%) of the colon * Presence of a stoma * Presence or history of a fistula * Contraindications to the use of golimumab or infliximab or anti-tumor necrosis factor (TNF-alpha) therapy per local prescribing information
- healthy Volunteers
- false
- maximum Age
- 17 Years
- minimum Age
- 2 Years
- sex
- ALL
- std Ages
- CHILD
Treatment arms and interventions
- arm Groups
- description
- Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. Following the Week 54 evaluations (end of main pivotal study) participants who are benefiting from golimumab at the discretion of the investigator may continue to receive SC golimumab in an extension period until end of study.
- intervention Names
- Drug: Golimumab
- label
- Group 1: Golimumab
- type
- EXPERIMENTAL
- description
- Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
- intervention Names
- Drug: Infliximab
- label
- Group 2: Infliximab
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Group 1: Golimumab
- description
- Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
- name
- Golimumab
- type
- DRUG
- arm Group Labels
- Group 2: Infliximab
- description
- Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
- name
- Infliximab
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 84
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Percentage of participants with clinical remission at Week 6 as assessed by the Mayo score was reported. Clinical remission was defined as a Mayo score of less than or equal to (\<=) 2 point, with no individual sub-score greater than (\>) 1. The Mayo score was sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.
- measure
- Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Mayo Score
- time Frame
- Week 6
- secondary Outcomes
- description
- Percentage of participants with symptomatic remission at Week 54 was reported. Symptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.
- measure
- Percentage of Participants With Symptomatic Remission at Week 54
- time Frame
- Week 54
- description
- Percentage of participants with clinical remission at Week 54 was reported. Clinical remission was defined as a Mayo score \<= 2 points, with no individual subscore \>1. The Mayo score was the sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.
- measure
- Percentage of Participants With Clinical Remission at Week 54 as Assessed by the Mayo Score
- time Frame
- Week 54
- description
- Percentage of participants with clinical remission at Week 54 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50 percent (%) of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number of stools per 24 hours (0-2 =0, 3-5 =5, 6-8 =10, \>8 =15); nocturnal bowel movement (no =0, yes =10); activity level (no limitation of activity =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI score = sum of scores of 6 items; score range of 0= no severity to 85= extreme severity.
- measure
- Percentage of Participants With Clinical Remission at Week 54 as Assessed by the Pediatric Ulcerative Colitis Activity Index Score (PUCAI) Score
- time Frame
- Week 54
- description
- Percentage of participants with clinical remission at Week 6 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50% of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number of stools per 24 hours (0-2 =0, 3-5 =5, 6-8 =10, \>8 =15); nocturnal bowel movement (no =0, yes =10); activity level (no limitation of activity =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI score = sum of scores of 6 items; score range of 0= no severity to 85= extreme severity.
- measure
- Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Pediatric Ulcerative Colitis Activity Index Score (PUCAI) Score
- time Frame
- Week 6
- description
- Clinical response was defined as a decrease from baseline in the Mayo score by \>= 30% and \>= 3 points, with either a decrease from baseline in the rectal bleeding subscore of \>= 1 or a rectal bleeding subscore of 0 or 1. The Mayo score was the sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.
- measure
- Percentage of Participants With Clinical Response at Week 6 as Assessed by the Mayo Score
- time Frame
- Week 6
- description
- Percentage of participants with endoscopic healing at Week 6 as assessed by the Mayo score was reported. Endoscopic healing was defined by an endoscopy subscore of the Mayo score of 0 or 1 based on local endoscopy. The Mayo score was the sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each subscore rated on a scale from 0 (normal) to 3 (severe), with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.
- measure
- Percentage of Participants With Endoscopic Healing at Week 6 as Assessed by the Mayo Score
- time Frame
- Week 6
- description
- Percentage of participants with endoscopic healing at Week 54 as assessed by the Mayo score was reported. Endoscopic healing is defined as an endoscopy subscore of the Mayo score of 0 or 1 based on local endoscopy. The Mayo score was the sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each subscore rated on a scale from 0 (normal) to 3 (severe), with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.
- measure
- Percentage of Participants With Endoscopic Healing at Week 54 as Assessed by the Mayo Score
- time Frame
- Week 54
- description
- Percentage of participants with clinical remission at Week 54 as assessed by the Mayo score for participants who were in clinical remission at week 6 was reported. Clinical remission was defined as a Mayo score \<=2 points, with no individual subscore \>1. The Mayo score was the sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.
- measure
- Percentage of Participants With Clinical Remission at Week 54 as Assessed by the Mayo Score for Participants Who Were in Clinical Remission at Week 6
- time Frame
- Week 54
- description
- Percentage of participants who were not receiving corticosteroids for at least 12 weeks prior to Week 54 and in clinical remission at week 54 was reported. Clinical remission was defined as a Mayo score \<=2 points, with no individual subscore \>1. The Mayo score was the sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.
- measure
- Percentage of Participants Who Were Not Receiving Corticosteroids for at Least 12 Weeks Prior to Week 54 and in Clinical Remission at Week 54
- time Frame
- Week 54
Full study description
- brief Summary
- The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC). In addition, the safety profile of golimumab, in pediatric participants with moderately to severely active UC will be assessed.
Source references
- references
- citation
- Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkus J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS. Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study. Inflamm Bowel Dis. 2026 Jun 1;32(6):1052-1061. doi: 10.1093/ibd/izaf322.
- pmid
- 41503939
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-0fe88b1b886f947f5288
- requested nct id
- NCT03596645
- primary nct id
- NCT03596645
- source kind
- fda_spl_label
- source record id
- 02ee9cf4-c6d6-4239-854e-7c5976977456
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 16ab11e1adabc299e050d89b6c30e6c109a4758565a7e86ce65e523092ef8fef
- payload
- application numbers
- BLA125289
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-0fe88b1b886f947f5288
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03596645
- occurrences
- context exact
- PsA, and 278 with AS. Three pooled, randomized, double-blind, controlled Phase 2/3 in 1233 SIMPONI-treated adult patients with UC (Trials UC-1, UC-2, and UC-3 (NCT03596645)) [see Clinical Studies (14.4) ] . An open-label trial in 69 SIMPONI-treated pediatric patients weighing at least 15 kg with UC (Trial UC-3) (NCT03596645) [see
- end
- 1719
- exact text
- NCT03596645
- start
- 1708
- context exact
- UC-3 (NCT03596645)) [see Clinical Studies (14.4) ] . An open-label trial in 69 SIMPONI-treated pediatric patients weighing at least 15 kg with UC (Trial UC-3) (NCT03596645) [see Clinical Studies (14.5) ] . The proportion of adult patients who discontinued treatment due to adverse reactions in the controlled Phase 3 trials through
- end
- 1873
- exact text
- NCT03596645
- start
- 1862
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/13/adverse_reactions/0
- source kind
- fda_spl_label
- source record id
- 02ee9cf4-c6d6-4239-854e-7c5976977456
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 056ca2b0d12b7b963aa8cc0aa47c65c0033ceee10a20971f2835df20a297e2bd
- spl effective time
- 20251029
- spl set id
- f86cb4a7-c358-4136-ae57-b32bda9bba00
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-ef292acb0b3b9b16257d
- requested nct id
- NCT03596645
- primary nct id
- NCT03596645
- source kind
- fda_spl_label
- source record id
- 02ee9cf4-c6d6-4239-854e-7c5976977456
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 8ab4c80985668c966d9cc9403e67eec33daebe791c5f4a8b6a6d1707c6cbfe69
- payload
- application numbers
- BLA125289
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-ef292acb0b3b9b16257d
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03596645
- occurrences
- context exact
- , 21%) p=0.004 14.5 Pediatric Ulcerative Colitis The efficacy and safety of SIMPONI was evaluated in a multi-center, open-label pediatric study of 69 patients (NCT03596645). Efficacy was assessed in 66 patients weighing at least 15 kg with moderately to severely active ulcerative colitis defined as a Mayo score of 6 to 12 with an
- end
- 22452
- exact text
- NCT03596645
- start
- 22441
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/13/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 02ee9cf4-c6d6-4239-854e-7c5976977456
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- a9dd8a4d187cc7fceb22d633ab61859921caab4a2927e9b8b2888dda41bc8fc9
- spl effective time
- 20251029
- spl set id
- f86cb4a7-c358-4136-ae57-b32bda9bba00
Preserved source evidence · Not medical advice